The Conference will return in November 2021, Register Your Interest Here

7:30 am Conference Registration & Networking

7:55 am Chair’s Opening Remarks

Enhancing Understanding of Fibrotic Disease Cell Types & Pathogenesis to Inform the Next Generation of Druggable Targets

8:00 am Single Cell RNA Sequencing

  • Scott MacDonnell Associate Director Cardiovascular, Fibrosis, & Renal Research, Regeneron Pharmaceuticals

8:30 am The Impact of Nintedanib on the Single Cell Seq Profile of Macrophage Populations in the Lungs of Mice

  • Karim Christian El Kasmi Laboratory Head Immunology & Respiratory Macrophage Biology Innate Immunity, Boehringer Ingelheim

9:00 am Targeting Senescent Cells: Friend or Foe?

9:30 am The Intricate Role of the Collagen Machinery in Fibrosis for Biomarker Use


  • The good and the bad collagens of fibrosis – and their role in organ function and extracellular matrix integrity
  • Identification of early efficacy and fibrosis progressors and regressors in fibrotic diseases based on the serological collagen profile

9:45 am

Speed Networking


This session is the ideal opportunity to get face-to-face time with many of the brightest minds working in the AFDD field and establish meaningful business relationships to pursue for the rest of the conference, all from the comfort of your own home or office.

10:30 am Morning Break & Networking

Identifying, Validating & Targeting: What are the Pathological Relationships & How do we Target Them?

11:00 am Interrogating & Visualizing Fibrosis to Identify Therapeutic Opportunities for Treating Age Related Macular Degeneration

11:30 am Targeting Metabolic Remodeling in Fibrosis

12:00 pm Targeting Fibrosis in the Liver With Pro-Apoptotic Drugs

12:30 pm Novel Cannabinoid Receptor 2 Selective Agonist for The Treatment of Fibrosis

  • Tama Evron Associate Director Research & Evaluation Research , Corbus Pharmaceuticals

1:00 pm

Lunch & Networking

2:00 pm Antibody-mediated Inhibition of CD38 for the Treatment of Inflammation and Fibrosis

2:30 pm Mechano-therapeutics: Targeting Mechanical Signalling in Fibrosis

  • David Lagares Assistant Professor of Medicine , Harvard Medical School

3:00 pm Quickfire on the Key Topics – Imaging, Modeling & Artificial Intelligence


This is your opportunity to engage in an interactive presentation and discussion on the hottest topics in the antifibrotic drug development space.

Join one of the sessions below to discover more about each speakers expertise through a short presentation and Q&A session with your peers.

Discovering the Role of Imaging in Quantification of Fibrotic Lung Disease & Implications for Other
Fibrotic Diseases
Deep Dive Into the Role of Machine Learning in Antifibrotic Therapy


Harnessing the Power of Emerging in Vitro Technologies


• Understanding common imaging findings for fibrotic diseases and their implications
• Exploring new imaging strategies for fibrosis analysis
• Outlining the value of quantifying fibrosis
• Exploring the potential for AI in anti-fibrotic therapeutics: can we use algorithms for improving the anti-fibrotic response?
• Uncovering the benefits &
drawbacks of patient-tailoring of anti fibrotics
• Determining the parameters to be used in fibrosis algorithms: focus on host-related, disease related & environment-related
Reflecting on the progress in precision cut slice technology over the past year
• Reviewing how to replicate organ culture
• Outlining how to ensure a
smoother transition into clinical trials
Mary Salvatore,
University of Columbia

Sachin Jambawalikar
Associate Director Research
& Evaluation Research

Illan Yaron,
Director, Department of
Medicine at Hadassah,
Hebrew University
Lee Borthwick,
Senior Lecturer in Fibrosis
Newcastle University

3:30 pm Afternoon Break & Networking

Tackling Translation: Bridging the Translational Gap by Assessing Current & Future Model Systems

4:00 pm A Comparison of CDA-HFD & High Cholesterol Diet Induced NASH Models Using Automated Quantitative Image Analysis & Deuterated Hydroxyproline Mass Spectrometry

4:30 pm Animal Models for Liver Fibrosis: Past, Present & Future

5:00 pm Studying a Preclinical Modeling Approach Using Humanized SCID Models of IPF

  • Cory Hogaboam Professor of Medicine & Adjunct Professor of Pathology, Cedars Sinai Medical Centre

5:30 pm Translational Packages & Moving Into the Clinic

  • Rob Slack Director of Pharmacology, Galecto

6:00 pm End of Conference Day One